Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
CagriSema — developed by Novo Nordisk ... Wegovy and Zepbound require weekly injections, and patients often have to contend with side effects that can include nausea, fatigue, vomiting, diarrhea ...